Biotest AG
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BTTAY research report →
Companywww.biotest.com
Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas.
- CEO
- Jorg Schuttrumpf
- IPO
- 2022
- Employees
- 2,495
- HQ
- Dreieich, DE
Price Chart
Valuation
- Market Cap
- $943.03M
- P/E
- -50.32
- P/S
- 4.83
- P/B
- 2.46
- EV/EBITDA
- -66.34
- Div Yield
- 0.12%
Profitability
- Gross Margin
- 20.45%
- Op Margin
- 0.12%
- Net Margin
- -7.60%
- ROE
- -4.79%
- ROIC
- 0.03%
Growth & Income
- Revenue
- $726.20M · 6.08%
- Net Income
- $26.40M · -79.21%
- EPS
- $0.36 · -77.81%
- Op Income
- $94.50M
- FCF YoY
- 189.20%
Performance & Tape
- 52W High
- $24.27
- 52W Low
- $22.80
- 50D MA
- $24.18
- 200D MA
- $24.24
- Beta
- 0.00
- Avg Volume
- 11
Get TickerSpark's AI analysis on BTTAY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BTTAY Coverage
We haven't published any research on BTTAY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BTTAY Report →